Previous studies have shown that canagliflozin, an SGLT2 inhibitor, has a significant impact on reducing the FIB-4 index.[30] On the other hand, dapagliflozin, which belongs to the same class, has no prominent effect on the FIB-4 index.[48,64] We used ultrasonography to assess the grade of fatty liver and the fibrosis-4 index to analyze the risk of liver fibrosis. Here, SLC5A2 is linked to fatty liver disease.